Pleural
Defining and targeting tumor-associated macrophages in malignant mesothelioma
Proceedings of the National Academy of Sciences of the United States of America 2023 February 28 [Link] Licun Wu, Mikihiro Kohno, Junichi Murakami, Amin Zia, Jonathan Allen, Hana Yun, Meilin Chan, Cristina Baciu, Mingyao Liu, Veronique Serre-Beinier, Michele De Palma, Emanuela Felley-Bosco, Jonathan Yeung, Trevor J Pugh, Marc de Perrot Abstract Defining the ontogeny of…
Read MoreNeurofibromatosis Type 2-Yes-Associated Protein and Transcriptional Coactivator With PDZ-Binding Motif Dual Immunohistochemistry Is a Reliable Marker for the Detection of Neurofibromatosis Type 2 Alterations in Diffuse Pleural Mesothelioma
Modern Pathology 2023 March [Link] Yan Li, Soo-Ryum Yang, Ying-Bei Chen, Prasad S Adusumilli, Ann Bialik, Francis M Bodd, Marc Ladanyi, Jessica Lopardo, Michael D Offin, Valerie W Rusch, William D Travis, Marjorie G Zauderer, Jason C Chang, Jennifer L Sauter Abstract Neurofibromatosis type 2 (NF2) loss occurs in approximately 30% to 50% of diffuse…
Read MoreMedical application of the monoclonal antibody SKM9-2 against sialylated HEG1, a new precision marker for malignant mesothelioma
Proceedings of the Japan Academy 2023 [Link] Shoutaro Tsuji, Kohzoh Imai Abstract Malignant pleural mesothelioma (MPM) is an aggressive tumor of the pleural cavity. Pathologically distinguishing MPM from other pleural lesions is often difficult. We searched for marker antigens to facilitate the pathological diagnosis of MPM and found useful markers for the pathological detection of…
Read MoreIdentification of Highly Sensitive Pleural Effusion Protein Biomarkers for Malignant Pleural Mesothelioma by Affinity-Based Quantitative Proteomics
Cancers 2023 January 19 [Link] Nicolai B Palstrøm, Martin Overgaard, Peter Licht, Hans C Beck Abstract Malignant pleural mesothelioma (MPM) is an asbestos-associated, highly aggressive cancer characterized by late-stage diagnosis and poor prognosis. Gold standards for diagnosis are pleural biopsy and cytology of pleural effusion (PE), both of which are limited by low sensitivity and…
Read MoreAdd-On Effect of Hemagglutinating Virus of Japan Envelope Combined with Chemotherapy or Immune Checkpoint Inhibitor against Malignant Pleural Mesothelioma: An In Vivo Study
Cancers 2023 February 1 [Link] Kazuma Sakura, Masao Sasai, Soichiro Funaki, Yasushi Shintani, Meinoshin Okumura, Yasufumi Kaneda Abstract Malignant pleural mesothelioma (MPM) is a refractory tumor because most of the lesions are already disseminated at diagnosis. Previously, the main treatment for MPM was combination chemotherapy. However, recently, immune checkpoint inhibitors (ICIs) are also used. For…
Read MoreGenomic and transcriptomic analyses identify a prognostic gene signature and predict response to therapy in pleural and peritoneal mesothelioma
Cell Reports: Medicine 2023 February 21 [Link] Nishanth Ulhas Nair, Qun Jiang, Jun Stephen Wei, Vikram Alexander Misra, Betsy Morrow, Chimene Kesserwan, Leandro C Hermida, Joo Sang Lee, Idrees Mian, Jingli Zhang, Alexandra Lebensohn, Markku Miettinen, Manjistha Sengupta, Javed Khan, Eytan Ruppin, Raffit Hassan Abstract Malignant mesothelioma is an aggressive cancer with limited treatment options…
Read MoreMEK1 drives oncogenic signaling and interacts with PARP1 for genomic and metabolic homeostasis in malignant pleural mesothelioma
Cell Death Discovery 2023 February 10 [Link] Haitang Yang, Yanyun Gao, Duo Xu, Ke Xu, Shun-Qing Liang, Zhang Yang, Amina Scherz, Sean R R Hall, Stefan Forster, Sabina Berezowska, Feng Yao, Adrian F Ochsenbein, Thomas M Marti, Gregor J Kocher, Ralph A Schmid, Patrick Dorn, Ren-Wang Peng Abstract Malignant pleural mesothelioma (MPM) is a lethal…
Read MoreCD70 and PD-L1 (CD274) co-expression predicts poor clinical outcomes in patients with pleural mesothelioma
The Journal of Pathology. Clinical Research 2023 February 8 [Link] Shingo Inaguma, Akane Ueki, Jerzy Lasota, Masayuki Komura, Asraful Nahar Sheema, Piotr Czapiewski, Renata Langfort, Janusz Rys, Joanna Szpor, Piotr Waloszczyk, Krzysztof Okoń, Wojciech Biernat, David S Schrump, Raffit Hassan, Markku Miettinen, Satoru Takahashi Abstract Diffuse pleural mesothelioma (PM) is a highly aggressive tumour typically…
Read MorePleurectomy and decortication are associated with better survival for bicavitary cytoreductive surgery for mesothelioma compared with extrapleural pneumonectomy
Journal of Thoracic and Cardiovascular Surgery 2022 December 14 [Link] R Taylor Ripley, Hudson M Holmes, Richard S Whitlock 2, Shawn S Groth, Cristian G Medina, Eugene A Choi, Bryan M Burt, Paul H Sugarbaker Abstract Objectives: Mesothelioma is a nearly uniformly fatal tumor. Multimodality therapy including cytoreductive surgery and chemotherapy is associated with long-term…
Read MoreImportance of Histopathological Grading for Treatment Selection in Malignant Mesothelioma
The Thoracic and Cardiovascular Surgeon 2023 February 3 [Link] İlteriş Türk, Gokturk Findik, Mehmet Çetin, Pinar Bicakcioglu, Selim Şakir Erkmen Gülhan, Koray Aydoğdu, Ülkü Yılmaz, Funda Demirağ Abstract Background: Complexities in TNM staging in epithelioid malignant pleural mesothelioma (MPM) may lead to errors in treatment selection, leading to major surgical interventions in patients with low…
Read More